Tag Archives: news

Life Science Nation Names Dealflow.eu as a Title Sponsor of RESI Europe Lisbon; Highlights EIC Participation Pathway

10 Feb

By Greg Mannix, VP, EMEA Business Development, LSN

New collaboration strengthens access for European life science innovators to engage global capital investors and licensing partners

Cambridge, MA and Lisbon, Portugal 

Life Science Nation (LSN) announced today a partnership with Dealflow.eu, naming the organization as a Title Sponsor of RESI Europe Lisbon. The collaboration supports the identification and preparation of high-potential European life science innovators and strengthens pathways for companies—where eligible—to leverage European Innovation Council (EIC) reimbursement mechanisms to participate in the RESI partnering ecosystem.

Dealflow.eu operates as a European innovation matchmaking and readiness platform, surfacing high-potential life sciences and deep-tech companies and supporting their engagement with global investors and strategic partners. Through this collaboration, Dealflow.eu will route a curated cohort of life science companies to RESI Europe Lisbon, positioning them in front of a global audience of investors and partners actively seeking early-stage opportunities.

RESI Europe Lisbon serves as the global activation layer of the Life Science Nation partnering ecosystem, connecting emerging technologies with investors and strategic partners through curated matchmaking, investor panels, and the Innovator’s Pitch Challenge. Unlike broad innovation showcases, RESI is purpose-built for early-stage life sciences partnering and capital formation, enabling qualified investors and partners to engage with technologies prepared for global scrutiny.

As part of this collaboration, Dealflow.eu will support eligible companies in accessing available reimbursement mechanisms—such as those offered through EIC programs, where applicable—to offset a portion of RESI Europe registration costs. This helps reduce participation barriers and expands access for promising European life sciences innovators to connect with global capital and strategic partner networks.

“This partnership strengthens the pathway from early innovation to global partnering,” said Dennis Ford, Founder and CEO of Life Science Nation. “Dealflow.eu operates upstream, identifying and preparing high-potential innovators for investor engagement. RESI operates downstream, providing the global activation environment where capital investors and strategic partners connect with emerging technologies. At the same time, programs such as those offered through the EIC can help support company participation and readiness along that journey.”

“We see RESI Europe as a highly complementary activation platform for the Dealflow.eu network,” said André Moraes Sarmento, Dealflow.eu. “Our mission is to connect high-potential innovators with investors, corporates, and strategic partners. This collaboration gives life science companies direct access to a global audience of qualified investors and licensing partners actively seeking early-stage technologies.”

The collaboration also includes coordinated programming at RESI Europe Lisbon, dedicated visibility opportunities for participating innovators, pre-conference preparation support, and continued alignment to strengthen pathways from European innovation to global market engagement.

RESI Europe Lisbon will take place in Lisbon, Portugal, bringing together global investors, strategic partners, and early-stage life sciences innovators across therapeutics, devices, diagnostics, digital health, and enabling technologies.

About Life Science Nation

Life Science Nation operates a global partnering and matching ecosystem that connects early-stage life sciences companies with qualified capital investors and licensing partners worldwide. Its platforms include the RESI Conference Series, LSN Labs entrepreneurial education and readiness programs, and global partnering campaign infrastructure.

About Dealflow.eu

Dealflow.eu is a European innovation matchmaking and readiness platform connecting high-potential innovators with investors, corporates, and strategic partners across Europe and globally.

Media Contact
Caitlin Dolegowski
Marketing Manager
Life Science Nation
c.dolegowski@lifesciencenatio.com
719-229-9290

Tags: , , , , , , , , , ,

Europe Doesn’t Have a Capital Problem. It Has a Translation Problem 

10 Feb

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

Across Europe, early-stage life science innovation isn’t held back by a lack of capital. It’s held back by a lack of translation. Brilliant ideas emerge every day from universities, startups, and labs, but too few of them cross the chasm into fundable, scalable ventures. Not because investors are uninterested, but because the signal is still forming. 

That is the gap RESI Europe is built to fill.

RESI Europe is intentionally focused on companies in the earliest stages of formation: seed, Series A, and Series B. In practical terms, that means seed financings up to $2M, Series A rounds up to $10M, and Series B rounds up to $50M. RESI is also cross-domain by design, connecting drugs, devices, diagnostics, and digital health under one roof so that cross-silo innovation can actually be seen and underwritten. These companies are not yet de-risked. They are still shaping their data, refining their narrative, and clarifying what kind of asset they are becoming. 

Unlike broad partnering events that are optimized for finished stories, RESI Europe’s product is filtration, not exposure. The investors and partners who participate specialize in early risk and engage before all the questions are answered, because that is when the partnership has the greatest leverage. And RESI does this at a registration cost typically around half of what many large European partnering conferences charge, making serious early-stage partnering accessible rather than exclusive. 

Partnering at this stage is not about acceleration.

It is about preparation. 

Europe does not need more capital flowing into the same mature assets. It needs a mechanism to translate potential into signal and the clarity to underwrite early-stage opportunities. Without that translation, meetings happen but decisions do not. Not because the science is weak, but because the story is still illegible.​ 

RESI Europe exists to make early innovation readable and to bring investors, strategics, and entrepreneurs together around the translational work that must happen before Phase II-level legibility is possible. 

Capital follows clarity.

Clarity requires translation.

That is what RESI Europe is built to deliver. 

Register for RESI Europe

Tags: , , , , , , , , , , , ,

Advancing Women’s Health Diagnostics Through Glycoproteomics: Proseek Bio at the Innovator’s Pitch Challenge 

3 Feb

Interview with Paula Cerqueira, VP of Scientific Strategy

Proseek Bio is advancing a new approach to women’s health diagnostics by translating cutting-edge glycoproteomics into clinically deployable tools. In this interview, Michelle Hill, CEO of Proseek Bio, discusses the company’s focus on ovarian cancer pre-surgical triage, the unmet clinical needs driving its platform, and how participating in the Innovator’s Pitch Challenge at RESI JPM shaped investor conversations as the company prepares for global expansion.

Michelle Hill
 CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): For those unfamiliar with Proseek Bio, how do you describe the company and its core technology or therapeutic focus? 

Michelle Hill (MH): Proseek Bio is an Australian diagnostics company focused on women’s health, developing blood-based tests designed to improve how complex conditions are assessed and managed in clinical practice. Ovarian cancer is our first indication, with an initial focus on pre-surgical triage.

Our platform is built on advanced glycoproteomics, integrating multiple protein biomarkers into a single algorithmic score to support clinical decision-making. Rather than relying on any one marker, this multi-analyte approach reflects the biological complexity of disease and enables more informative risk assessment at critical clinical decision points.

What differentiates Proseek Bio is our strong translational focus. The underlying science has been validated through years of academic and clinical research, and we are now converting that work into regulated, scalable diagnostic products for real-world healthcare systems. By targeting earlier decision points such as triage, we aim to support more appropriate referral and intervention, with a longer-term goal of expanding our platform across additional women’s health indications.

CD: What unmet need are you addressing, and why is now the right time for your approach? 

MH: A key unmet need in women’s health diagnostics is the lack of objective tools that reflect real-time disease biology at early clinical decision points. In ovarian cancer pre-surgical triage, clinicians must assess risk using tests with limited biological resolution, which can lead to unnecessary intervention or delayed specialist referral.

Proseek Bio addresses this gap through glycoproteomics, focusing on the glycans attached to proteins that regulate how those proteins function. While genes indicate what could happen and proteins act as messengers, glycan patterns reveal what disease is actively doing in the body. These modifications change early in cancer and cannot be resolved by genomics or standard immunoassays. By integrating glycan and protein signals into a multi-biomarker signature, our tests aim to deliver more informative risk stratification.

The timing is right because advances in clinical mass spectrometry and data analytics have made this biology clinically scalable, enabling integration into existing laboratory workflows and routine care.

CD: What was your experience participating in the Innovator’s Pitch Challenge at RESI JPM? 

MH: Our first time participating in the Innovator’s Pitch Challenge at RESI JPM was an energising experience. Pitching to a room filled with sophisticated investors and peers reinforced the importance of clear, disciplined storytelling when presenting complex diagnostic technologies.

As part of the Brisbane Economic Development Agency cohort, we were proud to represent Brisbane’s growing life sciences ecosystem. Beyond the pitch, the table showcase led to thoughtful conversations with investors and fellow founders who were genuinely engaged with both the clinical problem and our translational approach.

Overall, the experience was validating and motivating. It confirmed that our focus on clinically deployable diagnostics in women’s health resonates with a global audience, and it was rewarding to see that reflected in the recognition we received.

CD: Out of 94 Innovator’s Pitch Challenge companies, what do you think helped Proseek Bio stand out to judges and attendees? 

MH: Women’s health remains significantly underrepresented in diagnostic innovation, and that focus clearly resonated with judges and attendees. Ovarian cancer, in particular, represents a high-impact unmet need, especially at early clinical decision points such as pre-surgical triage.

Proseek Bio was the only diagnostics company on the podium, reflecting the distinctiveness of our approach. By applying glycoproteomics to analyse glycan and protein signatures together, we deliver a more biologically informative assessment of disease activity while remaining compatible with existing clinical laboratory workflows.

Importantly, we were able to clearly articulate not just the science, but the pathway to a regulated, scalable diagnostic product. That combination of unmet clinical need, novel biology, and disciplined execution helped differentiate Proseek Bio in a very strong field.

CD: How did RESI JPM impact discussions with investors, partners, or potential collaborators? 

MH: Being recognised on the Innovator’s Pitch Challenge podium gave investors immediate confidence in both the opportunity and the discipline behind the company, and it strengthened engagement with potential partners. Overall, RESI JPM acted as a signal amplifier, reinforcing Proseek Bio’s readiness for global investment and collaboration while accelerating meaningful follow-on conversations.

CD: Where does Proseek Bio currently stand in terms of fundraising, partnerships, or development milestones? 

MH: Proseek Bio is currently completing its Seed round to support development of our first product, OC-Triage. This funding is enabling a clinical study, implementation of a quality management system, and ISO accreditation to support pilot manufacturing, alongside evaluation of OC-Triage with Australian clinical laboratory partners.

In parallel, we are preparing for a Series A focused on U.S. market entry. RESI JPM provided an important opportunity to initiate discussions with U.S.-based clinical and laboratory partners, laying the groundwork for future validation and commercial pathways.

Together, these milestones reflect a transition from technology validation to execution as Proseek Bio advances toward regulated, clinically deployable diagnostics in women’s health.

CD: What upcoming achievements or milestones are you most excited to share with the life sciences community? 

MH: Over the coming year, we are focused on completing the OC-Triage product and establishing pilot manufacturing under an ISO-accredited quality system. These milestones represent an important transition from development to regulated production readiness.

In parallel, we are advancing clinical evaluation with laboratory partners, which will be critical in demonstrating real-world performance and scalability. Together, these steps mark a shift from innovation to execution.

What excites us most is seeing years of science translate into something tangible: a product that can be manufactured, validated, and ultimately used to support better clinical decisions for women.

Interested in pitching your company to a highly engaged investor audience focused on early-stage life science innovation? Applications are now open for the Innovator’s Pitch Challenge at RESI Europe. Selected companies receive direct feedback from a dedicated group of investors, access to 1:1 partnering, and visibility with global industry leaders.

Apply to pitch and position your company for meaningful investor conversations.

Apply to Pitch at RESI Europe 2026

Tags: , , , , , , , , , , , , , , , , , , , , , , , , ,

The Reality of European Global Partnering

27 Jan

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

Every March, early-stage life science teams spend thousands of euros to attend one of Europe’s biggest partnering weeks. They show up expecting investors, deal momentum, and progress. Most leave with something else: lots of vendor and service provider meeting requests, and a shorter cash runway.

For seed, Series A, and early Series B companies, Lisbon is not a winter party celebration. It is a stress test. And the platforms you choose will either compound your progress or quietly drain your capital.

The Cost Reality No One Likes to Say Out Loud

Standard passes and bundled “week in Lisbon” packages routinely run from 3,000 to 5,000 euros per person, before flights and hotels. For late-stage companies, that may be acceptable. For early-stage teams living on grants, founder savings, or a small seed round, it is a major bet.

By contrast, RESI Europe is typically priced in the 1,500-2,500 euro range because it is built specifically for founders, innovators, and regional cohorts raising seed, Series A, and early Series B funding. The goal is not to sell access at any cost. It is to make high-quality global partnering economically accessible at a stage when every euro still must justify itself.

Here is the problem. Many founders pay the higher prices and then discover that a large share of their so-called “investor” meetings are with service providers selling you something. The badge may say partner or advisor, but the economics are reversed. The startup becomes the customer, not the one being backed.

That outcome is not accidental. It is how large conference ecosystems monetize scale.

Lisbon Does Not Create Strategy. It Exposes It.

Big conference weeks amplify whatever strategy you bring. If you arrive without preparation and focus, you get more noise, more meetings you did not need, and a bigger bill. If you arrive with discipline, targeted investors, and a follow-up system, Lisbon can work.

The problem is that most mega-events are optimized for volume, not readiness. More people. More meetings. More urgency. That model works for late-stage transactions. It fails early-stage teams.

Early-stage companies need fewer things done well:

  • Investors and licensing partners who write first checks
  • Fewer vendor-driven meetings
  • A way to turn first conversations into real follow-up and progress

Proof That a Different Model Works

At JPM Week in January, RESI was designed explicitly around early-stage investing. Roughly 800 companies actively seeking capital and licensing deals participated alongside more than 800 qualified investors and licensing partners from around the world.

Participation was not open-ended. Investor categories were defined. Registrations per firm were capped to protect the signal in the room. The result was not fewer meetings. It was better, more compelling meetings.

That same discipline is what matters in Lisbon.

Why the LSN Partnering Backbone Beats Scale

LSN, owner of the RESI conference series, also owns a premier database of capital investors and licensing partners in the life sciences and offers programs for de-risking early-stage assets and for preparing and executing global roadshows, as well as services like BD Assist, which actually sets up the meetings for you. RESI has five global partnering events annually.

A partnering backbone asks different questions. Are you spending time with partners who fit your stage and product? Have you reduced scientific, regulatory, and execution risk before asking for capital? Do you have a system to re-engage after the week ends? When the answer is yes, Lisbon stops being a gamble.

The Real Fight

The real battle for Lisbon is not about who has the biggest crowd or the loudest brand. It is about who is actually built for early-stage innovation and who is pricing and designing their platform around scale.

For founders, investors, and regions focused on seed, Series A, and early Series B, the smart move is to start the week with early-stage as the priority, not the afterthought, and with “investor” meaning capital and licensing partner, not a sales pitch. Plug Lisbon into a backbone that keeps working after the noise fades. That is how early-stage teams win Lisbon. And that is where the fight really is.

If You’re Coming to Lisbon

RESI Europe will take place in Lisbon with an in-person conference followed by virtual partnering, giving early-stage teams both face-to-face and online access to global investors and licensing partners at founder-level pricing. If you want your Lisbon week to start in a room built for early-stage innovation, not a room selling to you, RESI is where that week should begin.

Register for RESI Europe

Tags: , , , , , , , , , , ,

Investor Panels at RESI Europe 2026 

27 Jan

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is pleased to introduce the investor panel lineup for RESI Europe, bringing together venture capital firms, family offices, corporate investors, and strategic partners actively funding and partnering across the global life science ecosystem. Designed to reflect how capital is being deployed today, these panels examine what investors are prioritizing, how partnership decisions are made, and what founders need to demonstrate to stand out in an increasingly selective market.

From pharma partnering and preclinical investing to digital health, medtech, and cross-border capital flows, the RESI Europe investor program offers a practical look at how decisions are being made across stages and sectors. Each session pairs candid investor perspectives with real-world expectations founders must meet to advance conversations beyond the first meeting.

Monday, March 23 – Investor Panels

9:00 – 9:50 AM | Pharma Partnering: Getting on Pharma’s Radar
As large pharmaceutical companies increasingly rely on external innovation, early-stage partnerships are becoming a core driver of pipeline growth. This session explores how pharma evaluates emerging science, which data packages resonate with business development teams, and how founders can structure partnership discussions that align with long-term strategic priorities.

10:00 – 10:50 AM | Funding New Science: How VCs Evaluate Preclinical Programs
With capital efficiency under intense scrutiny, therapeutic investors are rethinking how they assess risk and differentiation at the preclinical stage. Panelists will share how they evaluate programs ahead of clinical data, the milestones that matter most, and what founders must show to compete in today’s Series A environment.

11:00 – 11:50 AM | Family Offices: The Rise of the Venture Builder
Family offices have evolved into active healthcare investors, launching dedicated funds and building internal operating expertise. This discussion examines how these groups source deals, lead early-stage rounds, and make investment decisions differently from traditional institutional venture firms.

1:00 – 1:50 PM | Building Investable Medtech: Devices, Diagnostics, and De-risking
Investors in medtech are focused on solutions that combine technical innovation with clear clinical and regulatory pathways. This panel breaks down current investor interest across devices and diagnostics, highlighting the milestones that signal scalability and commercial readiness.

2:00 – 2:50 PM | Digital Health: Moving from Hype to Sustainable Value
As the digital health sector matures, investors are prioritizing solutions with measurable clinical and economic outcomes. Panelists will discuss where capital is being deployed, including AI-driven diagnostics and data platforms, and how companies can demonstrate long-term viability in real-world settings.

3:00 – 3:50 PM | Capital Without Borders: The European Life Science Landscape
Europe’s research ecosystem continues to produce world-class innovation, while investment dynamics increasingly span borders. This session explores how European life science companies can attract international capital, navigate regional differences, and compete on a global stage.

4:00 – 4:50 PM | Backing the First Believers: Deciding to Write the First Check
Pre-seed and formation-stage investors often commit capital before significant data exists, backing teams, vision, and early signals of execution. This panel examines how first-check investors assess founders, build conviction, and help shape companies into institutional-grade opportunities.

These investor panels are designed to foster meaningful dialogue between capital providers and innovators, creating informed conversations that continue beyond the stage and into partnering meetings.

Join the RESI Speaker Lineup
Are you an investor or strategic partner with valuable insights to share with early-stage life science companies? We are looking for dynamic speakers to join our RESI panels. 
Click here to submit your Speaker Interest Form today!

Registration for RESI Europe is now open.
Register with Super Early Bird rates and save €300. Super Early Bird pricing expires Friday, January 30.

Register for RESI Europe

Tags: , , , , , , , , , , , ,

Innovator’s Pitch Challenge Spotlight: Sania Therapeutics and a Controllable Approach to Gene Therapy 

27 Jan

Interview with Paula Cerqueira, VP of Scientific Strategy

Sania Therapeutics is developing a next-generation gene therapy platform focused on treating neurological symptoms driven by dysfunctional neural circuits. At RESI London, the company was recognized as a Third-Place winner in the Innovator’s Pitch Challenge and received the highest score from the judging panel, underscoring strong investor interest in its controllable and circuit-specific approach to gene therapy. In this interview, Sania Therapeutics shares its therapeutic focus, differentiated platform, and how participation in RESI has helped shape ongoing conversations with investors and strategic partners. 

Paula Cerqueira
 CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): For those just discovering Sania Therapeutics, how do you describe your company and therapeutic focus?
Paula Cerqueira (PC): Sania Therapeutics is developing a new class of controllable gene therapies designed to treat neurological symptoms driven by dysfunctional neural circuits. Our platform combines localized, low-dose AAV delivery that selectively targets specific neuronal subpopulations with patient-controlled activation, allowing us to precisely modulate hyperactive neurons, improving symptoms without adversely and permanently altering normal neural function. 

Our initial therapeutic target is a motor circuit disorder: spasticity. Our broader goal is to expand into additional motor and sensory indications where current treatment options are limited, invasive, or poorly tolerated. 

CD: What unmet medical need are you addressing, and what differentiates your approach?
PC: Millions of people live with debilitating neurological symptoms such as spasticity and pain disorders, yet existing treatments are often temporary, blunt, or invasive. Oral drugs frequently cause systemic side effects, while interventions like Botox or implanted devices require repeated procedures and provide limited relief. Despite the scale of this unmet need, there has been little meaningful innovation in this area for more than a decade. 

Sania’s approach is differentiated in two key ways. First, our proprietary platform enables selective targeting of the neural circuits that drive disease using localized, low-dose AAV delivery. This approach is intended to support a safer, more sustainable, and more scalable path for gene therapy than traditional systemic delivery. 

Second, our therapy is controllable. Patients can adjust the therapeutic effect using an oral activator, allowing symptom modulation over time. This puts patients in control while enabling precise and flexible therapeutic regulation. 

Our mission at Sania is to bring gene therapy into everyday clinical use by meaningfully improving the lives of people living with neurological conditions. While this is an ambitious goal, for patients who struggle daily with basic activities such as holding a child, we believe this approach has the potential to be truly transformative. 

CD: What was your experience participating in the Innovator’s Pitch Challenge at RESI London?
PC: Participating in the Innovator’s Pitch Challenge at RESI London was an extremely valuable experience. The format encouraged clarity and discipline in how we communicated both our science and long-term vision, and the audience questions reflected a high level of engagement from investors and industry leaders. 

Being recognized as a Third Place (First Place among judges in our session) winner among a strong and diverse group of companies was particularly meaningful, and it reinforced that there is a strong interest in approaches that rethink how gene therapy can be applied beyond ultra-rare indications. 

CD: How has the RESI platform influenced conversations with investors or strategic partners?
PC: RESI offered a valuable opportunity to present our work to a broad set of investors and strategic partners and to test our messaging with a highly informed audience. While many groups are understandably focused on later-stage opportunities, the platform helped us refine our positioning and identify areas of alignment for future conversations as the company progresses. 

Following the Innovator’s Pitch Challenge, we also initiated early, informal conversations that we expect to build on as the company continues to mature. 

CD: Where does Sania Therapeutics currently stand in terms of fundraising or partnerships?
PC: Sania Therapeutics is currently focused on advancing its lead spasticity program and platform toward key preclinical and IND-enabling milestones, while continuing to expand the broader platform supporting multiple motor and sensory indications. 

In parallel, we are building relationships with investors and strategic partners aligned with our long-term vision. As the platform matures and data advances, we expect to raise funding to support clinical entry of our lead program and the continued development of additional programs enabled by the platform, and we welcome conversations with groups interested in engaging early. 

CD: What upcoming milestones are most important for the company?
PC: Our near-term focus is on advancing our lead spasticity program across regulatory and manufacturing activities and initiating IND-enabling studies in 2026. Reaching that point will significantly de-risk the program and position us well as we move this innovative approach toward the clinic. 

In parallel, we are making meaningful progress on platform development to support expansion into additional motor and sensory indications. A key goal for the team this year is to validate our first sensory capsid in vivo, leveraging the same delivery and control principles demonstrated in our lead program. 

Applications are now open for the Innovator’s Pitch Challenge at RESI Europe. Life science and health tech companies seeking targeted feedback from a dedicated group of coordinated investors are encouraged to apply to participate in interactive pitching, partnering, and one-to-one meetings at RESI Europe. 

Apply to Pitch at RESI Europe 2026

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Proseek Bio claims global bronze in San Francisco, strengthening Brisbane’s MedTech credentials 

27 Jan

Brisbane’s world renowned MedTech sector has again been recognised on the global stage, with local company Proseek Bio securing bronze at the Innovator’s Pitch Challenge during J.P. Morgan Healthcare Week in San Francisco. 

Proseek Bio, a participant in Brisbane Economic Development Agency’s MedTech Global Accelerator, competed against more than 90 international health technology companies and was recognised for its groundbreaking work in non-invasive blood tests aimed at earlier and more accurate detection of ovarian cancer, an area of significant unmet global health need. 

This year’s achievement continues Brisbane’s strong run of podium success at one of the world’s most influential healthcare investor forums, highlighting the city’s growing capability to develop, commercialise and scale life-changing medical technologies. 

Brisbane’s Innovator’s Pitch Challenge podium finishes include: 

  • 2023 Gold: Field Orthopaedics; Bronze: Max Kelsen 
  • 2024 Silver: Convergence Medical; Bronze: Gelomics 
  • 2025 Gold: Kimaritec 
  • 2026 Bronze: Proseek Bio 

BEDA’s MedTech Global Accelerator cohort attended the RESI JPM 2026 Investor Forum, in partnership with Life Science Nation, a leading US investor and life sciences networking platform. 

Lord Mayor Adrian Schrinner said the result was another strong sign of Brisbane’s rising reputation in health and medical innovation. 

“Brisbane’s MedTech talent continues to make waves on the world stage,” Cr Schinner said. 

“Proseek Bio’s bronze finish shows just how much innovation is coming out of our city and that Brisbane can go toe-to-toe with the best in the world – especially in lifesaving areas like women’s health and cancer detection. 

“We’re proud to support our innovators in building the global connections and partnerships they need to turn great ideas into reality.” 

Proseek Bio Founder and CEO, Professor Michelle Hill said the recognition marked a significant milestone for the company. 

“Winning bronze in this highly competitive challenge is a tremendous achievement for us,” Professor Hill said. 

“It validates the potential of our technology to make a real difference in women’s health and accelerates our ability to attract global partners and investment. 

“Support through BEDA’s MedTech Global Accelerator and its international network has been critical to our journey.” 

Now in its fourth year, the accelerator has helped more than 30 visionary companies secure $246 million in capital and create more than 250 jobs in Brisbane.  

BEDA’s FY26 MedTech Global Accelerator cohort included Aptium AI, BiVACOR, Cool Beans Underwear, Fibrosoft, Ketim Technologies, LORAI Health, Proseek Bio, QBiotics Group Limited, STARCO and Talius. 

For more information about the MedTech Initiative, visit https://choose.brisbane.qld.au/business/key-industries/health/medtech 

Tags: , , , , , , , , ,

← Older Entries